Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
Paradione (paramethadione) is an oral solution small molecule approved in 1949 for seizure management. It is an oxazolidinedione class anticonvulsant with mechanism of action not fully characterized in modern literature. This is a legacy product with narrow current clinical use.
Minimal commercial investment signaled; legacy product with declining market presence and small team footprint expected.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on Paradione offers limited career momentum; the product is in late-stage lifecycle with minimal headcount and investment. Career value lies primarily in niche specialty positioning or transition management as the product approaches obsolescence.
Worked on PARADIONE at AbbVie? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.